Top Stories
Head-to-Head Superiority to High-Dose Dulaglutide: Innovent’s First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Primary Endpoints, Company Says
Top Stories Tamfitronics SAN FRANCISCO and SUZHOU, China, May 9, 2024